Response to “Adjuvant vitamin C in cardiac arrest patients undergoing renal replacement therapy: an appeal for a higher high-dose”
- 689 Downloads
KeywordsVitamin C Cardiac arrest Pharmacokinetics Continuous renal replacement therapy
Continuous renal replacement therapy
Continuous venovenous hemofiltration
We thank Honore et al.  for raising the issue of the optimal dose of vitamin C in cardiac arrest patients, especially those requiring continuous renal replacement therapy (CRRT). They propose to treat patients post-cardiac arrest with 6 g daily. However, the efficacy of vitamin C after cardiac arrest has not been settled yet, let alone the optimal dose. Up to now, only one small trial in septic patients compared two different doses: 200 mg/kg/day (~ 16 g/day) seemed superior to 50 mg/kg/day (~ 4 g/day) . All other studies in varying populations (but not after cardiac arrest) investigated a single dose (3 g up to 125 g/day). So, clinical studies on efficacy and dose in the cardiac arrest population are crucial before recommending an optimal dose. We are starting such a study (NCT03509662).
Honore et al. propose to double this dose to 12 g during CRRT based on three studies. Two of these studies included patients on intermittent chronic hemodialysis/diafiltration. One found a mean loss of 66 mg vitamin C per day (200 mg/week) , the other did not report total loss. The only study in patients on CRRT (continuous venovenous hemofiltration (CVVH)) reported a median loss of 93 (0–372) mg vitamin C per day. Furthermore, the mean plasma concentration in the CRRT patients was not lower than in the contemporary ICU population (43 (23–57) μmol/L vs 37 (28–108) μmol/L) . This suggests that not the CRRT but the critical illness is the cause of the low vitamin C concentrations.
In conclusion, vitamin C loss by CVVH does not seem to be higher than loss by the native kidney. So based on the scarce available data, it is not necessary to increase the vitamin C dose during CVVH above 2 g/day when normal plasma concentrations are targeted. Whether higher concentrations are beneficial needs to be shown. In our RCT in cardiac arrest patients more pharmacokinetic data will be collected.
We have received a grant from the Netherlands Organisation for Health Research and Development to perform an RCT with intravenous vitamin C in post-cardiac arrest patients.
Availability of data and materials
Available on request.
ASM drafted the original version of the manuscript. HJG, PWE, and HMO reviewed and revised the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Consent for publication
All authors have reviewed the final version of the manuscript and approve the manuscript for publication.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.